Unexpected Heterogeneity of Newly Diagnosed Multiple Myeloma Patients with Plasmacytomas
Martin Stork,
Sabina Sevcikova,
Tomas Jelinek,
Jiri Minarik,
Jakub Radocha,
Tomas Pika,
Lenka Pospisilova,
Ivan Spicka,
Jan Straub,
Petr Pavlicek,
Alexandra Jungova,
Zdenka Knechtova,
Viera Sandecka,
Vladimir Maisnar,
Roman Hajek,
Ludek Pour
Affiliations
Martin Stork
Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic
Sabina Sevcikova
Babak Myeloma Group, Department of Pathophysiology, Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic
Tomas Jelinek
Department of Hematooncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, 708 00 Ostrava, Czech Republic
Jiri Minarik
Department of Hemato-Oncology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, 779 00 Olomouc, Czech Republic
Jakub Radocha
4th Department of Medicine—Hematology, Charles University Hospital and Faculty of Medicine, 500 05 Hradec Kralove, Czech Republic
Tomas Pika
Department of Hemato-Oncology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, 779 00 Olomouc, Czech Republic
Lenka Pospisilova
Institute of Biostatistics and Analyses, Ltd., 625 00 Brno, Czech Republic
Ivan Spicka
1st Medical Department—Clinical Department of Hematology of the First Faculty of Medicine and General Teaching Hospital, Charles University, 128 08 Prague, Czech Republic
Jan Straub
1st Medical Department—Clinical Department of Hematology of the First Faculty of Medicine and General Teaching Hospital, Charles University, 128 08 Prague, Czech Republic
Petr Pavlicek
Department of Internal Medicine and Hematology, University Hospital Kralovske Vinohrady, 100 34 Prague, Czech Republic
Alexandra Jungova
Hematology and Oncology Department, Charles University Hospital, 323 00 Pilsen, Czech Republic
Zdenka Knechtova
Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic
Viera Sandecka
Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic
Vladimir Maisnar
4th Department of Medicine—Hematology, Charles University Hospital and Faculty of Medicine, 500 05 Hradec Kralove, Czech Republic
Roman Hajek
Department of Hematooncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, 708 00 Ostrava, Czech Republic
Ludek Pour
Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic
In multiple myeloma (MM), malignant plasma cells infiltrate the bone marrow. In some cases, plasma cells migrate out of the bone marrow creating either para-skeletal plasmacytomas (PS) or infiltrating soft tissues as extramedullary plasmacytomas (EMD). The aim of this study was to define risk groups in newly diagnosed MM (NDMM) patients with PS and EMD plasmacytomas. In total, 523 NDMM patients with PS plasmacytomas and 196 NDMM patients with EMD plasmacytomas were diagnosed in the Czech Republic between 2004 and 2021 using modern imaging methods. Patients’ data were analyzed from the Registry of Monoclonal Gammopathies of the Czech Myeloma Group. In NDMM patients with PS plasmacytomas, we found a subgroup with 5% of bone-marrow plasma cells and ≥3 plasmacytomas had the worst prognosis (mPFS: 19.3 months (95% CI: 13.4–28.8), p p < 0.001). Our results show association between tumor burden and prognosis of NDMM patients with plasmacytomas. In the case of PS plasmacytomas, NDMM patients with low BM PC infiltration have an excellent prognosis.